Healthcare Giants Spend Billions to Keep Medicare for All Off the Agenda

A Bill Buried Under Influence

In the modern history of American health policy, few proposals have generated as much grassroots energy and as little legislative movement as Medicare for All. The idea is simple: replace the fragmented system of private insurance, employer plans, Medicare, and Medicaid with a single government-run insurer. Polls have repeatedly shown majority approval for the concept. Yet in Congress, the bill has never come close to passage. A major factor, according to campaign-finance monitors and public-health researchers, is the staggering amount of money the health-care industry spends to keep it buried.

OpenSecrets, the nonpartisan group that tracks money in U.S. politics, reports that pharmaceutical and health-product companies are among the largest lobbying forces in Washington. In 2023, the sector reported more than $380 million in federal lobbying expenditures, exceeding every other industry. Hospitals, nursing homes, health professionals, and insurance companies added hundreds of millions more. Within the top ten individual lobbying operations, three are central players in the health-care economy: PhRMA, the pharmaceutical industry's main trade group; Blue Cross Blue Shield, the national federation of insurers; and the American Hospital Association. From 1998 through 2023, these sectors combined have spent well over $10 billion on lobbying. That total does not include campaign contributions, television advertisements financed by nonprofit front groups, or millions spent on state-level candidates.

The Money Machine

The mechanics of influence in Washington are complex, but the goal is straightforward. Lobbying money buys access: meetings with lawmakers, amendments drafted in the interests of donors, favorable questions at committee hearings, and, when necessary, a wall of opposition to anything that threatens the industry's bottom line. Medicare for All would be the single largest threat in the history of the private health-care industry. Under the legislation introduced by Senator Bernie Sanders, private insurers would be largely abolished and replaced with taxpayer-funded universal coverage. Drug companies would face direct government price negotiations. Hospitals would be paid at Medicare rates rather than the higher reimbursements they negotiate from private insurers. The Congressional Budget Office has not fully scored the latest version of the bill, but analysts agree that it would reduce administrative costs and shift financing from premiums to taxes.

Industry groups do not wait for bills to move before launching their defense. The Partnership for America's Health Care Future, a coalition funded by insurers, hospitals, and drugmakers, was created specifically to fight Medicare for All. Its advertisements warn of long waiting times, closed hospitals, and government rationing. Fact-checkers have repeatedly noted that the ads distort the details of the proposal, but the message has helped keep moderate lawmakers cautious. Even a diluted version of the idea, the public option, was stripped from major legislation after industry pressure in the first year of the Biden administration.

An Existential Threat to Business Models

For health insurers, a single-payer system is not an abstract debate; it is an existential threat. The largest health insurers in the United States generate hundreds of billions of dollars in annual revenue. Their profits depend on administering risk and processing claims. A single-payer system would eliminate that market entirely. Drug manufacturers face a similar peril. If a single public buyer became the sole purchaser of prescription drugs, prices would almost certainly fall sharply, reducing the revenue that companies use to fund research and development.

Industry representatives frame their opposition as a defense of patient choice, innovation, and affordability. Pharmaceutical companies argue that cutting their earnings would slow the development of new medicines. Insurers say market competition keeps premiums from rising even faster. Hospitals warn that Medicare reimbursement rates are too low to maintain staffing and rural access. These arguments are reinforced by the campaign donations that flow to lawmakers in both parties. Health-sector entities contributed more than $100 million in the 2023-2024 election cycle, according to federal records, with most of it going to incumbents with influence over health policy.

Public-health experts who support single-payer see the spending differently. They argue that the industry is using its massive resources to protect a system that is expensive, unequal, and administratively wasteful. Research on administrative costs in the United States, including billing and claims processing, has long shown that the system wastes hundreds of billions of dollars each year compared with simpler national models. From this perspective, the lobbying itself is a cost of reform: every year that Medicare for All remains off the agenda is another year of enormous private gain and fragmented public care.

Public Support Meets Political Reality

Given the industry's resources, it is perhaps not surprising that Medicare for All has not moved through Congress. A memorable 2019 hearing on universal coverage drew hours of testimony from economists and doctors, but no committee vote followed. Senator Sanders has introduced the bill several times, gathering support from many progressive House members, yet it has never received a floor vote in either chamber. Even presidential leadership has not changed the dynamic. After the 2020 election, allies of President Biden proposed to include a public option in his Build Back Better plan. The measure was dropped under pressure from the pharmaceutical and insurance industries and from moderate lawmakers concerned about the political and fiscal consequences.

Public-opinion data complicate the story. The Kaiser Family Foundation has found support for Medicare for All at or above 50 percent in many surveys. Yet the support is shallow. When questions mention the loss of private insurance or the need for higher taxes, approval drops sharply. The industry has spent heavily on exactly those points of vulnerability. Calls to “keep the system you have” have been powerful with older voters, who rely on Medicare and worry about disruption. In a country where most people are insured through employers, the promise of a total overhaul is both attractive and frightening.

The Road Ahead

The lobbying battle over Medicare for All is not going to end quickly. Even as the broader single-payer movement has faded from the top of the political agenda, industry spending has not decreased. In fact, the pharmaceutical industry has been fighting the next battle: the federal drug-price negotiation program created by the Inflation Reduction Act of 2022. Insurers and hospitals, meanwhile, continue to defeat state-level proposals for universal coverage and public options. Colorado rejected a single-payer initiative in 2016, and California's ambitious proposals have repeatedly stalled.

What comes next may be decided in the courts and in the next campaign cycle. The drug-price negotiation program faces legal challenges, and future Congresses could expand or narrow it depending on which party wins control. Democrats remain divided between supporters of single-payer and more incremental approaches, while Republicans have moved toward loosening insurance rules and increasing price transparency. In the background, the health-care industry's three major lobbying operations remain stationed within sight of the Capitol, funded by billions of dollars in premiums, hospital charges, and drug sales.

The central conclusion from the lobbying data is simple: the pursuit of universal health-care coverage in the United States is not only a debate about policy; it is a contest between public will and one of the most powerful industrial forces in American politics. As long as millions of dollars are available to remind lawmakers of the consequences of change, the status quo will have a strong defender. The question is whether the political pressure from ordinary voters will ever outweigh the financial pressure from those who profit from the current system.